PIK3CA and cancer: Second, a number of studies have demonstrated the role of E3 ligases affecting the PI3K pathway components negatively altering the activity of the PI3K pathway suggesting that targeted protein degraders, such as DUB inhibitors, may be used as a rational approach to target PI3K mutant cancers (55, 56).